EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 326 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR Studies Delve Deep into the Protein Machinery of Cancer Cells November 4, 2021 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. May 21, 2019 New analysis reveals Black women in England more likely to be... January 27, 2023 Pumpkin Season! October 27, 2020 Load more HOT NEWS Will Ponsegromab Be a Game Changer for Cancer Cachexia? Strong Independent Association of TILs with OS for Patients with ERBB2-positive... A peek behind the scenes: Just how are our funding decisions... New on NCI’s Websites for December 2023
